Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708588 · ClinicalTrials.gov registry record · Phase 4
Chewed Versus Integral Pill of Ticagrelor
A Phase 4 study of Percutaneous Coronary Intervention, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT03708588: Completed Phase 4 study of Percutaneous Coronary Intervention, sponsored by Wake Forest University Health Sciences.
NCT03708588 is a Phase 4 study of Percutaneous Coronary Intervention that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 112 participants, below the 5,216-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03708588, a Phase 4 study of Percutaneous Coronary Intervention, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.
Primary Outcome
Platelet function was measured using the VerifyNow P2Y12 Assay (Accumetrics, San Diego, CA). This test is a turbidimetric-based optical detection system that measures ADP (Adenosine diphosphate) - induced platelet agglutination using a proprietary algorithm to report values in PRU.
Conditions Studied
Interventions
- DRUG Ticagrelor
Study Locations (1)
Wisconsin
- Aurora Health Care, St. Luke's Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 4 |
What the finished NCT03708588 record still lists
NCT03708588 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 5,216-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 1 intervention - of which Ticagrelor is the first listed.
NCT03708588 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03708588 about?
NCT03708588 is a clinical study titled "Chewed Versus Integral Pill of Ticagrelor". Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pi...
What is the current status of trial NCT03708588?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2018-09-19. Estimated completion is 2021-07-31.
What conditions does trial NCT03708588 study?
This clinical trial studies the following conditions: Percutaneous Coronary Intervention.
What interventions are being tested in trial NCT03708588?
The interventions under investigation include: Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT03708588?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708588 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Percutaneous Coronary Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03708588's enrollment target sits among peer trials
112 11th of 12 higher than 2 of 12 other Percutaneous Coronary Intervention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Percutaneous Coronary Intervention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RECRUITING · Phase 4
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
ACTIVE NOT RECRUITING · NA
-
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
ACTIVE NOT RECRUITING
-
Precision PCI Registry
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI